Bruce Booth, a member of Kymera Therapeutics, Inc.'s board, completed a block of stock sales on April 14 and 15, 2026, disposing of 9,494 shares of the company's common stock and generating roughly $854,538 in gross proceeds. The trades were executed at prices ranging from $89.95 to $90.10 per share and were carried out under a pre-arranged Rule 10b5-1 trading plan.
The sales are broken down as follows: on April 14 Booth sold 4,159 shares at a weighted average price of $89.97. On April 15 he placed three separate transactions - 2,200 shares at a weighted average price of $89.95, and two lots of 2,750 and 385 shares respectively at $90.10 per share.
Coinciding with the sales, Booth exercised options to purchase 6,359 shares of Kymera's common stock at an exercise price of $14.18 per share. The option exercises totaled $90,170 in cash paid by Booth to acquire the shares.
Kymera's shares have appreciated substantially over the past year, rising 244% from the prior-year level. Despite that advance, the stock was trading at $86.14 at the time the report noted, which is below the prices at which Booth executed his sales. An InvestingPro analysis referenced in company reporting indicates the stock appears overvalued relative to its Fair Value, and Kymera carries a market capitalization of approximately $7.04 billion.
These insider transactions occur against a backdrop of pipeline and partnership activity. The U.S. Food and Drug Administration granted Fast Track designation to KT-621 for the treatment of moderate to severe eosinophilic asthma. KT-621 is currently being evaluated in two global Phase 2b studies that target both asthma and atopic dermatitis.
Separately, Gilead Sciences exercised its option to exclusively license KT-200, a CDK2 molecular glue degrader. That exercise triggered a $45 million milestone payment to Kymera. Under the parties' strategic collaboration, Gilead intends to advance KT-200 into IND-enabling studies, with an investigational new drug filing expected in 2027.
On the equity research front, H.C. Wainwright reaffirmed a Buy rating on Kymera and retained a price target of $134.00 after discussions with company management about ongoing trials. Stephens adjusted its outlook by raising its price target to $100 while maintaining an Overweight rating, following Kymera's fourth-quarter and full-year 2025 financial results.
Kymera also plans to present data from its KT-621 BroADen Phase 1b clinical trial in atopic dermatitis at the American Academy of Dermatology 2026 Annual Meeting. Together, the regulatory designation, collaboration milestone and upcoming data presentations reflect active development and partner engagement across Kymera's pipeline.
Summary of transactional details and corporate developments:
- Insider sales: 9,494 shares sold April 14-15, 2026; proceeds ~ $854,538; sale prices between $89.95 and $90.10.
- Option exercise: 6,359 shares acquired at $14.18 per share for $90,170 paid by Booth.
- Trading mechanics: All sales executed under a Rule 10b5-1 plan.
- Valuation context: Stock up 244% over the past year, trading at $86.14, with an InvestingPro view that the stock is overvalued and a market cap near $7.04 billion.
- Pipeline and partner updates: FDA Fast Track for KT-621 in eosinophilic asthma; Gilead exercised option on KT-200 triggering a $45 million payment and planning IND-enabling work with an expected IND filing in 2027.
- Analyst activity: H.C. Wainwright reiterates Buy and $134 PT; Stephens raises PT to $100 and keeps Overweight rating.